Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Patients who cannot receive tenofovir disoproxil fumarate or tenofovir alafenamide because of current or high risk of renal dysfunction should be treated with a fully suppressive antiretroviral regimen that does not include either drug, and renally dosed entecavir should be added to the regimen (Management Guidelines)[DHHS OI]
    • For HIV/HBV-coinfected patients with renal dysfunction but with creatinine clearance of 30 mL/min to 59 mL/min, an ART regimen containing tenofovir alafenamide and emtricitabine is preferred
    • For HIV/HBV-coinfected patients with creatinine clearance < 30 mL/min, adding renally dosed entecavir to a suppressive non-tenofovir–containing ART regimen is preferred

Action required